Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 7/20 | 0.39 |
| ▸ | TK1 | P04183 | 4/20 | 0.37 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.36 |
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7192452 | 0.91 | TK2 (0.35) | TK2TK1 | |
| SCHEMBL3300455 | 0.84 | RNASE1 (0.37) | TK2TK1RNASE1 | |
| SCHEMBL5668664 | 0.82 | TK1 (0.39) | TK2TK1RNASE1TYMP | |
| SCHEMBL28162665 | 0.75 | RNASE1 (0.41) | TK2TK1RNASE1TYMP | |
| SCHEMBL28182722 | 0.74 | TK2 (0.46) | TK2TK1 | |
| SCHEMBL6851558 | 0.74 | TK1 (0.34) | TK2TK1 | |
| SCHEMBL28190357 | 0.73 | TK2 (0.47) | TK2TK1 | |
| SCHEMBL8744222 | 0.73 | TK2 (0.41) | TK2TK1 | |
| SCHEMBL3300461 | 0.73 | TK2 (0.38) | TK2TK1RNASE1TYMP | |
| SCHEMBL8053437 | 0.72 | TK1 (0.42) | TK2TK1TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 368 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003520042-A | — | — | 2003-07-02 | — | — | JP | claimed |
| EP-1250157-A1 | ANTISENSE MODULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-10-23 | — | — | EP | claimed |
| WO-2001052902-A1 | ANTISENSE MODULATION OF INDUCIBLE NITRIC OXIDE SYNTHASE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | claimed |
| EP-1631235-A4 | COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS INC (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-1631659-A4 | MODULATION OF THE RNA INTERFERENCE PATHWAY | ISIS PHARMACEUTICALS INC (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1613728-A4 | MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 1 EXPRESSION | ISIS PHARMACEUTICALS INC (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1718762-A1 | ANTISENSE OLIGONUCLEOTIDE MODULATION OF STAT3 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2006-11-08 | — | — | EP | disclosed |
| EP-1664267-A2 | MODULATION OF GROWTH HORMONE RECEPTOR EXPRESSION AND INSULIN-LIKE GROWTH FACTOR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1660682-A2 | ANTISENSE MODULATION OF p38 MITOGEN ACTIVATED PROTEIN KINASE EXPRESSION | Isis Pharmaceuticals, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1648910-A2 | ANTISENSE MODULATION OF STEAROYL-COA DESATURASE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2006-04-26 | — | — | EP | disclosed |
| EP-1633302-A2 | MODULATION OF APOLIPOPROTEIN (A) EXPRESSION | Isis Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2000032818-A1 | ANTISENSE MODULATION OF CELLULAR INHIBITOR OF APOPTOSIS-2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-2000031296-A1 | ANTISENSE MODULATION OF INTERLEUKIN-15 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000031103-A1 | ANTISENSE MODULATION OF MEK2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000031105-A1 | ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-BETA EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000030686-A1 | ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-ALPHA EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000031111-A1 | ANTISENSE MODULATION OF NF-KAPPA-B P65 SUBUNIT EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000031106-A1 | ANTISENSE MODULATION OF MEK1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000008042-A1 | AMINOOXY-MODIFIED NUCLEOSIDIC COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
| WO-1999049065-A1 | ANTISENSE MODULATION OF HUMAN MDM2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-30 | — | — | WO | disclosed |